International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia

Ravi Savarirayan*, Penny Ireland, Melita Irving, Dominic Thompson, Inês Alves, Wagner A.R. Baratela, James Betts, Michael B. Bober, Silvio Boero, Jenna Briddell, Jeffrey Campbell, Philippe M. Campeau, Patricia Carl-Innig, Moira S. Cheung, Martyn Cobourne, Valérie Cormier-Daire, Muriel Deladure-Molla, Mariana del Pino, Heather Elphick, Virginia FanoBrigitte Fauroux, Jonathan Gibbins, Mari L. Groves, Lars Hagenäs, Therese Hannon, Julie Hoover-Fong, Morrys Kaisermann, Antonio Leiva-Gea, Juan Llerena, William Mackenzie, Kenneth Martin, Fabio Mazzoleni, Sharon McDonnell, Maria Costanza Meazzini, Josef Milerad, Klaus Mohnike, Geert R. Mortier, Amaka Offiah, Keiichi Ozono, John A. Phillips, Steven Powell, Yosha Prasad, Cathleen Raggio, Pablo Rosselli, Judith Rossiter, Angelo Selicorni, Marco Sessa, Mary Theroux, Matthew Thomas, Laura Trespedi, David Tunkel, Colin Wallis, Michael Wright, Natsuo Yasui, Svein Otto Fredwall

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)


Achondroplasia, the most common skeletal dysplasia, is characterized by a variety of medical, functional and psychosocial challenges across the lifespan. The condition is caused by a common, recurring, gain-of-function mutation in FGFR3, the gene that encodes fibroblast growth factor receptor 3. This mutation leads to impaired endochondral ossification of the human skeleton. The clinical and radiographic hallmarks of achondroplasia make accurate diagnosis possible in most patients. However, marked variability exists in the clinical care pathways and protocols practised by clinicians who manage children and adults with this condition. A group of 55 international experts from 16 countries and 5 continents have developed consensus statements and recommendations that aim to capture the key challenges and optimal management of achondroplasia across each major life stage and sub-specialty area, using a modified Delphi process. The primary purpose of this first International Consensus Statement is to facilitate the improvement and standardization of care for children and adults with achondroplasia worldwide in order to optimize their clinical outcomes and quality of life.

Original languageEnglish
JournalNature Reviews Endocrinology
Early online date26 Nov 2021
Publication statusE-pub ahead of print - 26 Nov 2021


Dive into the research topics of 'International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia'. Together they form a unique fingerprint.

Cite this